<DOC>
	<DOCNO>NCT00537017</DOCNO>
	<brief_summary>The purpose study assess long term safety SCH 420814 ( preladenant ) participant moderate severe Parkinson 's Disease take L-Dopa/dopa decarboxylase inhibitor and/or dopamine agonist . All participant must participate main study ( P04501 ; NCT00406029 ) entitle `` A Phase 2 , 12 Week , Double Blind , Dose Finding , Placebo Controlled Study Assess Efficacy Safety Range SCH 420814 Doses Subjects With Moderate Severe Parkinson 's Disease Experiencing Motor Fluctuations Dyskinesias . ''</brief_summary>
	<brief_title>Follow Up Safety Study SCH 420814 Subjects With Parkinson 's Disease ( P05175 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Participants must participate P04501 . Participants must &gt; =30 year age , diagnosis moderate severe idiopathic Parkinson 's disease . Participants must regimen LDopa and/or dopamine agonist . Participants discontinue Study P04501 experience serious adverse event ( SAE ) Participants form druginduced atypical parkinsonism , cognitive impairment , psychosis Participants take tolcapone Participants participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>